A detailed history of Commonwealth Equity Services, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Commonwealth Equity Services, LLC holds 1,170,856 shares of BMY stock, worth $67.8 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares
1,170,856
Previous 1,202,754 2.65%
Holding current value
$67.8 Million
Previous $50 Million 21.28%
% of portfolio
0.09%
Previous 0.08%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

SELL
$39.66 - $51.75 $1.27 Million - $1.65 Million
-31,898 Reduced 2.65%
1,170,856 $60.6 Million
Q2 2024

Jul 31, 2024

BUY
$40.25 - $52.99 $3.2 Million - $4.21 Million
79,413 Added 7.07%
1,202,754 $50 Million
Q1 2024

Apr 29, 2024

BUY
$47.98 - $54.4 $795,604 - $902,060
16,582 Added 1.5%
1,123,341 $60.9 Million
Q4 2023

Feb 06, 2024

SELL
$48.48 - $57.85 $4.64 Million - $5.53 Million
-95,627 Reduced 7.95%
1,106,759 $56.8 Million
Q3 2023

Oct 23, 2023

SELL
$57.89 - $64.73 $2.56 Million - $2.86 Million
-44,144 Reduced 3.54%
1,202,386 $69.8 Million
Q2 2023

Aug 10, 2023

BUY
$63.71 - $70.74 $1.01 Million - $1.12 Million
15,881 Added 1.29%
1,246,530 $79.7 Million
Q1 2023

May 11, 2023

BUY
$65.71 - $74.53 $3.75 Million - $4.25 Million
57,046 Added 4.86%
1,230,649 $85.3 Million
Q4 2022

Feb 07, 2023

BUY
$68.48 - $81.09 $1.79 Million - $2.12 Million
26,194 Added 2.28%
1,173,603 $84.4 Million
Q3 2022

Nov 14, 2022

SELL
$0.13 - $76.84 $816 - $482,401
-6,278 Reduced 0.54%
1,147,409 $81.6 Million
Q2 2022

Jul 19, 2022

SELL
$72.62 - $79.98 $305,584 - $336,555
-4,208 Reduced 0.36%
1,153,687 $88.8 Million
Q1 2022

May 04, 2022

SELL
$61.48 - $73.72 $941,258 - $1.13 Million
-15,310 Reduced 1.3%
1,157,895 $84.6 Million
Q4 2021

Jan 31, 2022

SELL
$53.63 - $62.52 $621,089 - $724,044
-11,581 Reduced 0.98%
1,173,205 $73.1 Million
Q3 2021

Oct 29, 2021

SELL
$59.17 - $69.31 $606,788 - $710,774
-10,255 Reduced 0.86%
1,184,786 $70.1 Million
Q2 2021

Aug 11, 2021

BUY
$61.91 - $67.42 $2.9 Million - $3.16 Million
46,899 Added 4.08%
1,195,041 $79.9 Million
Q1 2021

May 04, 2021

BUY
$59.34 - $66.74 $3.21 Million - $3.61 Million
54,089 Added 4.94%
1,148,142 $72.5 Million
Q4 2020

Feb 11, 2021

SELL
$57.74 - $65.43 $365,263 - $413,910
-6,326 Reduced 0.57%
1,094,053 $67.9 Million
Q3 2020

Nov 05, 2020

BUY
$57.43 - $63.64 $3.66 Million - $4.05 Million
63,654 Added 6.14%
1,100,379 $66.3 Million
Q2 2020

Aug 12, 2020

BUY
$54.82 - $64.09 $4.2 Million - $4.92 Million
76,694 Added 7.99%
1,036,725 $61 Million
Q1 2020

May 11, 2020

BUY
$46.4 - $67.43 $606,587 - $881,512
13,073 Added 1.38%
960,031 $53.5 Million
Q4 2019

Feb 05, 2020

BUY
$49.21 - $64.19 $7.1 Million - $9.26 Million
144,193 Added 17.96%
946,958 $60.8 Million
Q3 2019

Oct 30, 2019

BUY
$42.77 - $50.71 $365,127 - $432,911
8,537 Added 1.07%
802,765 $40.7 Million
Q2 2019

Jul 19, 2019

BUY
$44.62 - $49.34 $2.56 Million - $2.83 Million
57,384 Added 7.79%
794,228 $36 Million
Q1 2019

May 13, 2019

BUY
$45.12 - $53.8 $2.84 Million - $3.38 Million
62,915 Added 9.34%
736,844 $35.2 Million
Q4 2018

Feb 11, 2019

BUY
$48.76 - $63.23 $353,510 - $458,417
7,250 Added 1.09%
673,929 $35 Million
Q3 2018

Nov 06, 2018

BUY
$55.19 - $62.25 $139,741 - $157,617
2,532 Added 0.38%
666,679 $41.4 Million
Q2 2018

Jul 31, 2018

SELL
$50.53 - $62.98 $1.1 Million - $1.38 Million
-21,854 Reduced 3.19%
664,147 $36.8 Million
Q1 2018

May 14, 2018

SELL
$59.92 - $68.98 $1.16 Million - $1.33 Million
-19,285 Reduced 2.73%
686,001 $43.4 Million
Q4 2017

Feb 12, 2018

BUY
$59.94 - $65.35 $42.3 Million - $46.1 Million
705,286
705,286 $43.2 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Commonwealth Equity Services, LLC Portfolio

Follow Commonwealth Equity Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Commonwealth Equity Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Commonwealth Equity Services, LLC with notifications on news.